SlideShare a Scribd company logo
1 of 18
Disease
Management
Diabetes Mellitus
Disease management
Disease management is the concept of reducing health care
costs and improving quality of life for individuals with
chronic conditions by preventing or minimizing the effects of
the disease through integrated care.
Disease management is a proactive, multidisciplinary,
systematic approach to health care
• delivery that Includes all members with chronic disease.
• Supports the provider-patient relationship and plan of
care.
• Optimizes patient care through prevention and proactive
interventions based on evidence-based guidelines.
Diabetes Mellitus
Diabetes mellitus is the most common of the
endocrine disorders. It is a chronic metabolic
condition, characterized by hyperglycemia
due to impaired insulin production and
secretion with or without insulin resistance.
Diabetes mellitus may be classified according
to etiology, by far the most common types
being type 1 and type 2 diabetes.
Type 1 diabetes
Type 1 diabetes is a disease
characterized by the
destruction of the insulin-
producing pancreatic β-cells.
In more than 90% of cases, β-
cell destruction is associated
with autoimmune disease.
Type 2 diabetes
Type 2 diabetes is caused by a
relative insulin deficiency and
the body’s inability to effectively
use insulin. The pancreas is able
to produce some insulin;
however, as insulin resistance
increases, the effectiveness of
circulating insulin decreases, and
the amount produced is not
sufficient to meet the body’s
requirements.
Type 1 diabetes Type 2 diabetes
Epidemiology
0.5M
children are living
with type 1 diabetes
worldwide
It’s the farType 2 diabetes is
much more common than
type 1, accounting for
approximately 90% of
people with diabetes.thest
planet from the sun
1 in 11 adults
have diabetes
Approximately 50–
60% of patients with
type 1 will present
before 20 years of age
• Type 2 diabetes is more common in people of African, African-
Caribbean, and South Asian family origin.
• Estimates in the UK suggest that type 2 diabetes currently affects
approximately 3.2 million adults with a conirmed diagnosis, and a
further 500,000 are thought to be undiagnosed (Diabetes UK, 2016)
1 in 10 by
2040
Pathogenesis
Pathogenesis of type I diabetes
An autoimmune disease-The
immune system mediates the
destruction of βcells.
• It develops in genetically
susceptible individuals who are
exposed to an environmental
factor that triggers the
autoimmune response; β-cell
destruction ensues.
• Overt Type1 DM does not
appear until about 90% of β-cells
are destroyed.
Pathogenesis of type II diabetes
• Risk factor Obesity (greatest risk
factor) Genetics Age (insulin
production decreases with age).
• Obesity is associated with increased
plasma levels of free fatty acids,
which make muscles more insulin
resistant, reducing glucose uptake.
• Lack of compensation in type II
diabetic patients in normal
individuals, the pancreas secretes
more insulin in response to free fatty
acids, thus neutralizing the excess
glucose.
Insulin–glucose relationship detailing the actions of insulin.
Diabetes Diagnosis
5.8
• Screen all adults between ages 40 and 70 every 3 years.
• For those with risk factors for diabetes (obesity, family history, history
of gestational diabetes), start screening earlier. Some recommend early
screening for African Americans and Native Americans.
• Test anyone with signs or symptoms of diabetes
Clinical presentation of Diabetes
Progression of type I diabetes mellitus.
Pharmacotherapy of Diabetes
Avoid
Enjoy
• Diet and exercise are especially effective in
obese and sedentary patients (who constitute
most type II diabetic patients).
• Most patients, however, do not lose enough
weight to control glucose levels through diet
and exercise alone and will require
pharmacologic treatment.
• Glycemic control minimizes risks for
nephropathy, neuropathy, and retinopathy in
both Type 1 and 2 DM, and decreases risk
for cardiovascular disease for Type 1 DM.
Non-Insulin Medication
Non-Insulin Medication
• Intensive insulin therapy
• Insulin sliding
• scale Modifying insulin
Method of administration.
• Self-administered by sc
injection in abdomen,
buttocks, arm, and leg.
• Given intravenously for
emergency ketoacidosis.
Insulin based medication
Regimens
 Most type I diabetic patients require 0.5 to 1.0 unit/kg per day to
achieve acceptable glycemic control.
 Start with a conservative dose (0.2 units/kg) and adjust the regimen
according to the patient’s glucose levels.
 Many different regimens exist, and every patient has unique needs.
Intensive insulin therapy
 Long-acting insulin is given once daily in the evening.
 These more aggressive therapies have been shown to significantly
decrease the incidence of diabetes complications such as retinopathy
and microalbuminuria when compared to prior regimens.
 With intensive insulin therapy, the risk for hypoglycemia is a
serious concern.
Inpatient management of diabetic patients (sliding scale)
• An insulin sliding scale (SSI) of regular
insulin doses given according to bedside
finger-stick glucose determinations is
helpful in controlling blood glucose
levels in the hospital setting
• Once insulin therapy is started, a blood
glucose goal of 140 to 180 mg/dL should
be targeted for most patients.
Modifying insulin
• Physical activity—depending on the intensity of the activity, decrease
insulin dosage 1 to 2 units per 20 to 30 minutes of activity.
• During illness, administer all of the routine insulin. Many episodes of
DKA occur during episodes of illness.
• Stress and changes in diet require dosing adjustments.
• Patients undergoing surgery should get one-third to one-half of the
usual daily insulin requirement that day, with frequent monitoring and
adjustments, as necessary.
Surgical treatment
 Surgical weight loss therapy (i.e., gastric bypass) is an effective
treatment for some patients, including adolescents. Additionally, islet
cell transplantation offers definitive treatment for selected qualified
patients.

More Related Content

Similar to Diabetes

Advanced PharmacologyDiabetes is a group of metabolic diseas
Advanced PharmacologyDiabetes is a group of metabolic diseasAdvanced PharmacologyDiabetes is a group of metabolic diseas
Advanced PharmacologyDiabetes is a group of metabolic diseas
milissaccm
 
Case study - DM 2, CKD 4
Case study - DM 2, CKD 4Case study - DM 2, CKD 4
Case study - DM 2, CKD 4
Reynel Dan
 
DIABETES MELLITUS -DR Nagaraj kotli sir.pptx
DIABETES MELLITUS -DR Nagaraj kotli sir.pptxDIABETES MELLITUS -DR Nagaraj kotli sir.pptx
DIABETES MELLITUS -DR Nagaraj kotli sir.pptx
NRKAOFFICIAL
 
diabetes mellitus & their complications
diabetes mellitus & their complicationsdiabetes mellitus & their complications
diabetes mellitus & their complications
Shamili Kaparthi
 
Diabetes tech program_final
Diabetes tech program_finalDiabetes tech program_final
Diabetes tech program_final
Krystin Fields
 

Similar to Diabetes (20)

Diabetes Mellitus 1.pptx
Diabetes Mellitus 1.pptxDiabetes Mellitus 1.pptx
Diabetes Mellitus 1.pptx
 
General medicine update for every doctor
General medicine update for every doctorGeneral medicine update for every doctor
General medicine update for every doctor
 
type 1 diabetes: update
type 1 diabetes: updatetype 1 diabetes: update
type 1 diabetes: update
 
Diabetes mellitus ppt
Diabetes mellitus pptDiabetes mellitus ppt
Diabetes mellitus ppt
 
Diabetes (2) (1)
Diabetes (2) (1)Diabetes (2) (1)
Diabetes (2) (1)
 
#Diabetes mellitus disease ppt presentation
#Diabetes mellitus disease ppt presentation#Diabetes mellitus disease ppt presentation
#Diabetes mellitus disease ppt presentation
 
Advanced PharmacologyDiabetes is a group of metabolic diseas
Advanced PharmacologyDiabetes is a group of metabolic diseasAdvanced PharmacologyDiabetes is a group of metabolic diseas
Advanced PharmacologyDiabetes is a group of metabolic diseas
 
2. diabetes mellitus
2. diabetes mellitus2. diabetes mellitus
2. diabetes mellitus
 
Diabetes mellitus (dm) and DKA
Diabetes mellitus (dm) and DKADiabetes mellitus (dm) and DKA
Diabetes mellitus (dm) and DKA
 
Diabetes mellitus (dm) And DKA
Diabetes mellitus (dm) And DKADiabetes mellitus (dm) And DKA
Diabetes mellitus (dm) And DKA
 
Case study - DM 2, CKD 4
Case study - DM 2, CKD 4Case study - DM 2, CKD 4
Case study - DM 2, CKD 4
 
DIABETES MELLITUS -DR Nagaraj kotli sir.pptx
DIABETES MELLITUS -DR Nagaraj kotli sir.pptxDIABETES MELLITUS -DR Nagaraj kotli sir.pptx
DIABETES MELLITUS -DR Nagaraj kotli sir.pptx
 
diabetes mellitus & their complications
diabetes mellitus & their complicationsdiabetes mellitus & their complications
diabetes mellitus & their complications
 
Diabetes
DiabetesDiabetes
Diabetes
 
Non-pharmacological Management of Diabetes Mellitus.pptx
Non-pharmacological Management of Diabetes Mellitus.pptxNon-pharmacological Management of Diabetes Mellitus.pptx
Non-pharmacological Management of Diabetes Mellitus.pptx
 
Diabetes tech program_final
Diabetes tech program_finalDiabetes tech program_final
Diabetes tech program_final
 
Gobindgarh public school
Gobindgarh public schoolGobindgarh public school
Gobindgarh public school
 
Express Clinics Diabetes Health Check Up (69 Parameters) @ Rs. 2,499
Express Clinics Diabetes Health Check Up (69 Parameters) @ Rs. 2,499Express Clinics Diabetes Health Check Up (69 Parameters) @ Rs. 2,499
Express Clinics Diabetes Health Check Up (69 Parameters) @ Rs. 2,499
 
Diabetes Mellitus & Nurses Role
Diabetes Mellitus & Nurses RoleDiabetes Mellitus & Nurses Role
Diabetes Mellitus & Nurses Role
 
endocrine.pptx
endocrine.pptxendocrine.pptx
endocrine.pptx
 

Recently uploaded

VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
JRRolfNeuqelet
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancementsCAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
Naveen Gokul Dr
 
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Abortion pills in Kuwait Cytotec pills in Kuwait
 

Recently uploaded (20)

Anti viral drug pharmacology classification
Anti viral drug pharmacology classificationAnti viral drug pharmacology classification
Anti viral drug pharmacology classification
 
ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failure
 
Histopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseasesHistopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseases
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas Hospital
 
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
 
Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
Stereochemistry & Asymmetric Synthesis.pptx
Stereochemistry & Asymmetric Synthesis.pptxStereochemistry & Asymmetric Synthesis.pptx
Stereochemistry & Asymmetric Synthesis.pptx
 
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptxGross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
 
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing WellnessSigns It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
 
Face and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxFace and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptx
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
 
Varicose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas HospitalVaricose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas Hospital
 
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
 
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancementsCAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
 
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
 

Diabetes

  • 2. Disease management Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care. Disease management is a proactive, multidisciplinary, systematic approach to health care • delivery that Includes all members with chronic disease. • Supports the provider-patient relationship and plan of care. • Optimizes patient care through prevention and proactive interventions based on evidence-based guidelines.
  • 3. Diabetes Mellitus Diabetes mellitus is the most common of the endocrine disorders. It is a chronic metabolic condition, characterized by hyperglycemia due to impaired insulin production and secretion with or without insulin resistance. Diabetes mellitus may be classified according to etiology, by far the most common types being type 1 and type 2 diabetes.
  • 4. Type 1 diabetes Type 1 diabetes is a disease characterized by the destruction of the insulin- producing pancreatic β-cells. In more than 90% of cases, β- cell destruction is associated with autoimmune disease. Type 2 diabetes Type 2 diabetes is caused by a relative insulin deficiency and the body’s inability to effectively use insulin. The pancreas is able to produce some insulin; however, as insulin resistance increases, the effectiveness of circulating insulin decreases, and the amount produced is not sufficient to meet the body’s requirements.
  • 5. Type 1 diabetes Type 2 diabetes
  • 6. Epidemiology 0.5M children are living with type 1 diabetes worldwide It’s the farType 2 diabetes is much more common than type 1, accounting for approximately 90% of people with diabetes.thest planet from the sun 1 in 11 adults have diabetes Approximately 50– 60% of patients with type 1 will present before 20 years of age • Type 2 diabetes is more common in people of African, African- Caribbean, and South Asian family origin. • Estimates in the UK suggest that type 2 diabetes currently affects approximately 3.2 million adults with a conirmed diagnosis, and a further 500,000 are thought to be undiagnosed (Diabetes UK, 2016) 1 in 10 by 2040
  • 7. Pathogenesis Pathogenesis of type I diabetes An autoimmune disease-The immune system mediates the destruction of βcells. • It develops in genetically susceptible individuals who are exposed to an environmental factor that triggers the autoimmune response; β-cell destruction ensues. • Overt Type1 DM does not appear until about 90% of β-cells are destroyed. Pathogenesis of type II diabetes • Risk factor Obesity (greatest risk factor) Genetics Age (insulin production decreases with age). • Obesity is associated with increased plasma levels of free fatty acids, which make muscles more insulin resistant, reducing glucose uptake. • Lack of compensation in type II diabetic patients in normal individuals, the pancreas secretes more insulin in response to free fatty acids, thus neutralizing the excess glucose.
  • 9. Diabetes Diagnosis 5.8 • Screen all adults between ages 40 and 70 every 3 years. • For those with risk factors for diabetes (obesity, family history, history of gestational diabetes), start screening earlier. Some recommend early screening for African Americans and Native Americans. • Test anyone with signs or symptoms of diabetes
  • 11. Progression of type I diabetes mellitus.
  • 12. Pharmacotherapy of Diabetes Avoid Enjoy • Diet and exercise are especially effective in obese and sedentary patients (who constitute most type II diabetic patients). • Most patients, however, do not lose enough weight to control glucose levels through diet and exercise alone and will require pharmacologic treatment. • Glycemic control minimizes risks for nephropathy, neuropathy, and retinopathy in both Type 1 and 2 DM, and decreases risk for cardiovascular disease for Type 1 DM.
  • 15. • Intensive insulin therapy • Insulin sliding • scale Modifying insulin Method of administration. • Self-administered by sc injection in abdomen, buttocks, arm, and leg. • Given intravenously for emergency ketoacidosis. Insulin based medication
  • 16. Regimens  Most type I diabetic patients require 0.5 to 1.0 unit/kg per day to achieve acceptable glycemic control.  Start with a conservative dose (0.2 units/kg) and adjust the regimen according to the patient’s glucose levels.  Many different regimens exist, and every patient has unique needs. Intensive insulin therapy  Long-acting insulin is given once daily in the evening.  These more aggressive therapies have been shown to significantly decrease the incidence of diabetes complications such as retinopathy and microalbuminuria when compared to prior regimens.  With intensive insulin therapy, the risk for hypoglycemia is a serious concern.
  • 17. Inpatient management of diabetic patients (sliding scale) • An insulin sliding scale (SSI) of regular insulin doses given according to bedside finger-stick glucose determinations is helpful in controlling blood glucose levels in the hospital setting • Once insulin therapy is started, a blood glucose goal of 140 to 180 mg/dL should be targeted for most patients.
  • 18. Modifying insulin • Physical activity—depending on the intensity of the activity, decrease insulin dosage 1 to 2 units per 20 to 30 minutes of activity. • During illness, administer all of the routine insulin. Many episodes of DKA occur during episodes of illness. • Stress and changes in diet require dosing adjustments. • Patients undergoing surgery should get one-third to one-half of the usual daily insulin requirement that day, with frequent monitoring and adjustments, as necessary. Surgical treatment  Surgical weight loss therapy (i.e., gastric bypass) is an effective treatment for some patients, including adolescents. Additionally, islet cell transplantation offers definitive treatment for selected qualified patients.